Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan

Fürst, Daniel E.; Amato, Anthony A.; Iorga, Şerban R.; Gajria, Kavita; Fernandes, Ancilla W.

doi:10.1002/mus.23302

Cited by 138 publications

(101 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Annual incidence in the USA has been reported between 4.2 and 7.9 cases per 100,000 person years and annual prevalence between 14 and 25.3 per 100,000 individuals [2,3]. By comparison, the prevalence for inherited muscular dystrophies ranges from 19.8 to 25.1 per 100,000 person years [4][5][6].…”

Section: Introductionmentioning

confidence: 98%

Myositis Mimics

Michelle

Mammen

2015

Curr Rheumatol Rep

View full text Add to dashboard Cite

Patients with autoimmune myositis typically present with muscle weakness, elevated serum levels of muscle enzymes, and abnormal muscle biopsies. However, patients with other acquired myopathies or genetic muscle diseases may have remarkably similar presentations. Making the correct diagnosis of another muscle disease can prevent these patients from being exposed to the risks of immunosuppressive medications, which benefit those with myositis, but not those with other types of muscle disease. Here, we review some of the most common acquired and inherited muscle diseases that can mimic autoimmune myositis, including inclusion body myositis, limb girdle muscular dystrophies, metabolic myopathies, mitochondrial myopathies, and endocrine myopathies. We emphasize aspects of the medical history, physical exam, laboratory evaluation, and muscle biopsy analysis that can help clinicians distinguish myositis mimics from true autoimmune myositis.

show abstract

Section: Introductionmentioning

confidence: 98%

Myositis Mimics

Michelle

Mammen

2015

Curr Rheumatol Rep

View full text Add to dashboard Cite

show abstract

“…1 Dermatomyositis (DM) and polymyositis (PM) are the two main types in which the incidence and prevalence of DM is 1.4 and 5.8 cases per 100,000 persons in a recent study in U.S. with female preponderance and a higher prevalence among older age group, while the prevalence of PM is 9.7 per 100 thousand people. 2 Despite their different pathological characteristics, both disease types cause muscle inflammation and tissue damage because of deposition of immune complexes, activation of cytokines, and action of adhesion molecules and chemokines. 3,4 Except for progressive proximal weakness, some patients suffer dyspnea due to interstitial lung disease (ILD) or respiratory muscle weakness, dysphagia related to pharyngeal or esophageal involvement, heart failure or arrhythmia caused by myocarditis, and gastrointestinal bleeding from vasculopathy of the enteron.…”

mentioning

confidence: 99%

Serum Interleukin-18 Level is Associated With Disease Activity and Interstitial Lung Disease in Patients With Dermatomyositis

et al. 2017

View full text Add to dashboard Cite

Objectives:This study aims to demonstrate the utilization of serum interleukin-18 (IL-18) level as a biomarker for disease activity and organ damage in patients with dermatomyositis (DM) or polymyositis (PM) using the Myositis Disease Activity Assessment Tool. Patients and methods: Forty-nine patients (13 males, 36 females) with idiopathic inflammatory myopathies were enrolled in the study. Patients were diagnosed with DM (n=33) or PM (n=16). Twenty age-and sex-matched healthy volunteers (9 males, 11 females) who were determined to be free of autoimmune disease were included as a control group. Disease activity and organ damage were assessed with Myositis Disease Activity Assessment Tool. Serum IL-18 level was measured with enzyme-linked immunosorbent assay and the differences between patient groups were determined. Results: The mean ages of DM or PM patients were 44 and 45, respectively. Interstitial lung disease (ILD) was found in 24 patients (48.98%), including 18 patients with DM (54.55%) and six patients with PM (37.5%). There was no significant difference of disease duration between DM patients (17.5±22.3 months) and PM patients (14.9±28.7 months). Serum IL-18 level in DM (669.2±528.1 pg/mL) was significantly higher than that in the control group (388.3±139.4 pg/mL, p=0.017), but no significant difference was observed between the PM and control group. IL-18 was significantly higher in DM patients with ILD (890.5±618.8 pg/mL) than in patients without ILD (403.8±84.8 pg/mL, p=0.003). It was significantly elevated in patients with severe disease activity (1001.7±694.2 pg/mL) than in those with moderate (485.3±102.2 pg/mL) or mild disease activity (421.0±270.2 pg/mL) (p=0.039). In DM patients, IL-18 was significantly correlated with global disease activity and disease activity in the skin, lung, and heart. Conclusion: Serum IL-18 level was higher in patients with DM and this was associated with disease activity and ILD complication. Thus, it can be used as a valuable serological marker for DM disease activity and ILD complication.

show abstract

“…It is a rare disease, with a low incidence and prevalence. The incidence estimates range from 0.14 to 1.4 cases per 100,000 person-years [2][3][4][5][6][7], and prevalence ranges from 5.9 to 21.42 per 100,000 population [2,4,6]. DM affects all ages, but females are affected twice as often as males [5].…”

Section: Introductionmentioning

confidence: 99%

Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand

et al. 2015

View full text Add to dashboard Cite

show abstract

Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan

Abstract: The incidence and prevalence of idiopathic inflammatory myopathies in the managed care plan studied was higher than previously reported in the United States. Because of the limitations inherent in claims analysis, additional research is needed to substantiate these results.

Cited by 138 publications

References 20 publications

Myositis Mimics

Myositis Mimics

Serum Interleukin-18 Level is Associated With Disease Activity and Interstitial Lung Disease in Patients With Dermatomyositis

Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand

Contact Info

Product

Resources

About